Loading
Total declarations
Company
▲ Purchases (12 ops.)
▼ Sales (0 ops.)
Latest filing published 09 Feb 2026 for Galectin Therapeutics INC, €688. Read the official filing
Filing timeline
BuySaleKary Eldred
Insider track record
Disclosed buys
12
Disclosed sells
0
Signal history
Closed purchases
Market purchases
12
Positive at T+90
63%
Median T+90
+1.9%
Based on 8 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -19.9%Entry US$2.76 · Close at T+90 US$2.21
- -29.8%Entry US$4.03 · Close at T+90 US$2.83
- +22.3%Entry US$2.82 · Close at T+365 US$3.45
- +254.8%Entry US$1.15 · Close at T+365 US$4.08
- +105.1%Entry US$2.55 · Close at T+365 US$5.23
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Kary Eldred: trading record in brief
All filings by Kary Eldred on record concern Galectin Therapeutics Inc. In total, 12 filings cover trades dated from 25 January 2023 to 6 February 2026.
Every open-market trade on record is a purchase: 12 purchases worth €27k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2026 alone, the filings show 1 purchase and no sales.
The median purchase comes to €1,407. 5 out of 11 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster. Ninety days after publication, 8 purchases show a median change of +1.9%, with the price up in 63% of them. They describe history only and say nothing certain about the share price ahead.
The record was last updated on 9 February 2026 with an open-market purchase (€688) in Galectin Therapeutics Inc. Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Kary Eldred
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations12 total
300 shares@ US$2.702.7% of flowCommon StockSEC:0001133416-26-000048:0
Canonical exit: 7 May 2026 (T+90)
700 shares@ US$3.738.3% of flowCommon StockSEC:0001133416-25-000074:0
Canonical exit: 23 Mar 2026 (T+90)
700 shares@ US$3.738.8% of flowCommon StockSEC:0001133416-25-000078:0
Canonical exit: 23 Mar 2026 (T+90)
1,000 shares@ US$2.9259.9% of flowCommon StockSEC:0001133416-25-000035:0
Canonical exit: 19 Oct 2025 (T+90)
13,469 shares@ US$0.8242.2% of flowCommon StockSEC:0001133416-24-000064:0
Canonical exit: 24 Mar 2025 (T+90)
500 shares@ US$2.604.8% of flowCommon StockSEC:0001133416-24-000060:0
Canonical exit: 21 Jan 2025 (T+90)
400 shares@ US$2.393.5% of flowCommon StockSEC:0001133416-24-000048:0
Canonical exit: 20 Oct 2024 (T+90)
400 shares@ US$2.393.5% of flowCommon StockSEC:0001133416-24-000046:0
Canonical exit: 15 Apr 2024 (T+90)
500 shares@ US$1.78583.2% of flowCommon StockSEC:0001133416-24-000004:0
Canonical exit: 15 Apr 2024 (T+90)
1,598 shares@ US$1.78610.1% of flowCommon StockSEC:0001133416-23-000065:0
Canonical exit: 17 Oct 2023 (T+90)
1,000 shares@ US$1.59115.9% of flowCommon StockSEC:0001133416-23-000043:0
Canonical exit: 22 May 2023 (T+90)
1,300 shares@ US$1.115.3% of flowCommon StockSEC:0001133416-23-000006:0
Canonical exit: 25 Apr 2023 (T+90)
12 of 12 declarations
